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To gain further insight into the role of Raf-1 in normal cell growth, c-raf-1 mRNA expression, Raf-1 protein
production, and Raf-l-associated kinase activity in normal human T cells were analyzed. In contrast to the
constitutive expression of Raf-1 in continuously proliferating cell lines, c-raf-1 mRNA and Raf-1 protein levels
were barely detectable in freshly isolated Go T lymphocytes. Previous work with fibroblasts has suggested that
Raf-1 plays a signaling role in the Go-G1 phase transition. In T cells, triggering via the T-cell antigen receptor
(TCR)-CD3 complex (TCR/CD3) resulted in an approximately fourfold increase in c-raf-1 mRNA. In addition,
the promotion of G, progression by interleukin 2 (IL-2) was associated with a 5- to 10-fold immediate/early
induction of c-raf-1 mRNA, resulting in up to a 12-fold increase in Raf-1 protein expression. TCR/CD3
activation did not alter the phosphorylation state of Raf-1, whereas interleukin 2 receptor stimulation resulted
in a rapid increase in the phosphorylation state of a subpopulation of Raf-1 molecules progressively increasing
throughout Gl. These findings were complemented by assays for Raf-l-associated kinase activity which
revealed a gradual accumulation of serine and threonine autokinase activity in Raf-1 immunoprecipitates
during G1, which remained elevated throughout DNA replication.
c-raf-1 is the normal cellular homolog of v-raf, a trans-
forming gene originally discovered as an insert in a murine
Moloney sarcoma virus isolate (49). The c-raf-1 gene en-
codes a 70- to 75-kDa cytoplasmic phosphoprotein, Raf-1,
that has associated serine- and threonine-specific kinase
activity (7, 8, 40). On the basis of sequence analysis, the
Raf-1 protein can be divided into two domains of approxi-
mately equal sizes, an amino N-terminal regulatory domain
and a carboxy C-terminal catalytic kinase unit (48). The
N-terminal domain is thought to exert negative regulatory
control over the C-terminal kinase domain, in that all onco-
genic forms of Raf-1 identified thus far contain deletions or
other mutations of the N-terminal half of the molecule (8).
Moreover, experimental mutations of c-raf-1 by the con-
struction of 5' gene deletions reveal that virtually the entire
N-terminal regulatory domain of Raf-1 must be removed
before the kinase activity becomes fully constitutive and
before transforming activity for murine embryonic fibro-
blasts (3T3 cells) becomes manifest (25, 61, 64).
Since v-raf transforms murine 3T3 cells and since c-raf-1
5' deletion mutants can induce DNA replication in serum-
starved 3T3 cells (60), Raf-1 kinase activity is thought to play
a key role in signaling cell cycle progression and DNA
replication. Work to date has centered on very early events
in this process, and the regulated activation of the Raf-1
kinase by platelet-derived growth factor (PDGF) has re-
cently been the focus of considerable interest. Experiments
show that the Raf-1 molecule is induced to associate with the
PDGF-, receptor upon PDGF-receptor binding (41). Subse-
quently, there is an increase in Raf-1 phosphorylation and its
associated kinase activity (42).
In order to gain further information regarding the role of
* Corresponding author.
Raf-1 in cell growth regulation, we focused on normal human
T lymphocytes (T cells). T cells are an ideal system for
growth regulation studies, because they exist normally in a
noncycling (Go) state yet can be made to enter the cell cycle
semisynchronously simply by activating the T-cell antigen
receptor (TCR)-CD3 complex (TCR/CD3) (58). A series of
experiments has now established that T-cell cycle progres-
sion occurs as a result of the sequential expression of a series
of genes. In particular, the TCR/CD3 complex initiates Go to
G, transition, whereby the cells are made competent to
proliferate by the expression of the genes encoding the
receptor for the T-cell growth factor, interleukin 2 (IL-2) (12,
14, 51, 58, 65). Simultaneously, the IL-2 gene itself is
transcribed and the IL-2 receptor (IL-2-R) interaction pro-
motes G, progression to DNA replication.
Because T-cell cycle progression depends on two distinct
and well-characterized cell surface receptors, we sought to
determine whether Raf-1 is involved in T-cell growth control
by coupling to either or both of these receptor systems and
their associated signaling pathways. The TCR/CD3 complex
stimulates tyrosine-specific phosphorylation (3, 27, 43) and
activates the phosphatidyl-inositol pathway, raising free
intracellular calcium and activating protein kinase C (PKC)
(67). By comparison, the IL-2-R interaction stimulates ty-
rosine phosphorylation (1, 35, 54, 55) but does not activate
phosphatidyl-inositol hydrolysis (36-38).
Thus far, c-raf-1 mRNA expression has been found to be
constitutive and to remain invariant throughout the cell cycle
(13, 63, 68). However, most studies to date have utilized
established cell lines, all of which have various alterations of
growth regulation (45). Upon examination of freshly iso-
lated, resting T cells, we found c-raf-1 message and protein
expression to be barely detectable. Activation of the TCR/
CD3 complex resulted in an -4-fold increase in c-raf-1
mRNA expression, and IL-2-R stimulation led to a further 5-
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to 10-fold immediate/early induction of c-raf-1 mRNA
expression. The combined effect of inducing c-raf-1 mRNA
resulted in up to a 12-fold increase in Raf-1 protein levels
which accumulate throughout G1. However, signaling via
the two systems differed, in that TCR activation did not alter
the phosphorylation state of Raf-1, whereas IL-2-R stimula-
tion was associated with Raf-1 hyperphosphorylation and an
increase in associated kinase activity. These changes in
Raf-1 accumulate during G1 and remain elevated throughout
DNA synthesis, implicating Raf-1 as functioning in later
stages of the cell cycle, a concept which has not previously
been considered.
MATERIALS AND METHODS
Reagents. Cyclosporin A (CsA) (Sandoz, Hanover, N.J.)
was dissolved in ethanol-Tween 80 and stored as a 1-mg/ml
stock as recommended by the manufacturers. 4-P-12-Myris-
tate-13-acetate (PMA), phorbol-12-13-dibutyrate (PdBU),
NM,02-dibutyryl cyclic AMP (db-cAMP), and cyclohexi-
mide (CHX) were obtained from Sigma Chemical Co. (St.
Louis, Mo.). PMA and PdBU were solubilized in dimethyl
sulfoxide to yield stock concentrations of 5 mg/ml. db-cAMP
and CHX were solubilized in RPMI 1640 medium to yield
stock concentrations of 10 mg/ml. Stock solutions of all
reagents were diluted to the appropriate final concentrations
in RPMI 1640 medium prior to each incubation.
Homogeneous human recombinant IL-2 was provided by
Takeda Chemical Industries (Osaka, Japan) as a 1.0-mg/ml
solution in ammonium acetate buffer (pH 5.0).
Cell culture. Venous whole blood was drawn from healthy
human donors, and peripheral blood mononuclear cells
(PBMCs) were isolated by Ficoll-Hypaque discontinuous
gradient centrifugation and cultured at 106 cells per ml in
complete media consisting of RPMI 1640 medium (GIBCO
Laboratories, Grand Island, N.Y.) supplemented with 10%o
heat-inactivated (56°C for 30 min) fetal bovine serum (Sterile
Systems, Logan, Utah), L-glutamine (200 ,ug/ml), penicillin
G (50 U/ml), and gentamicin (50 ,ug/ml) (GIBCO). Cells were
stimulated for 72 h by monoclonal antibodies reactive to the
T3 (CD3) component of the T-cell receptor complex (OKT3,
1:10,000 dilution; Ortho Pharmaceuticals). The cells were
washed to remove a-CD3 and any IL-2 produced in situ and
then were recultured in IL-2-free medium for 48 h or
maintained for 10 to 12 days at concentrations between 2 x
105 and 1 x 106 cells per ml by supplementation with
recombinant IL-2 (500 pM) (62). After 13 to 15 days, the cells
(>99% T cells, represented by CD4+ and CD8+ subpopula-
tions) were washed and cultured without IL-2 for 36 to 48 h
to ensure their reaccumulation in the early G1 phase of the
cell cycle (23). IL-2-R expression was achieved by exposure
to 50 ng of PdBU per ml for 10 to 12 h, after which the cells
were extensively washed and kept in complete medium
without IL-2 for 12 to 14 h. The expanded, IL-2-R-positive T
cells were kept in IL-2-free medium or stimulated into G,
cell cycle progression by the addition of IL-2 (1 nM).
High-affinity IL-2-R expression was monitored by binding of
radioiodinated IL-2 as described previously (66).
An enriched primary human T-cell population was ob-
tained from PBMCs by using a modification of the method
previously described (10). Monocytes and natural killer and
B cells were removed while T cells were positively selected
with a-CD3 monoclonal antibodies. PBMCs (5 x 106 cells
per ml) were cultured in serum-free medium at 22°C for 60
min in the presence of a lysosomotropic compound, 5 mM
L-leucine methyl ester hydrochloride (Sigma). This treat-
ment selectively lyses monocytes and natural killer cells.
Cells were washed and then incubated with 5 ,ug of a-CD3
monoclonal antibody (64.1 [immunoglobulin G2a], a gener-
ous gift of E. Vitetta, University of Texas Health Science
Center at Dallas) per ml for 60 min at 4°C. After the removal
of unbound 64.1, the cells were allowed to adhere to goat
anti-mouse Fc (Organon Teknika Corp., West Chester,
Pa.)-coated petri dishes for 60 min at 4°C. Unbound CD3(-)
cells were removed by gentle aspiration and washed three
times with cold media. This cell separation procedure typi-
cally yielded a population of T cells which was >98% T11+
as determined by flow cytometric analysis. Adherent, resting
T cells were immediately harvested or subsequently incu-
bated at 37°C in the presence or absence of various additives
to initiate T-cell activation.
[3H]thymidine ([3H]TdR; 2.0 jXCi/ml; Schwartz/Mann Di-
vision, Becton Dickinson) incorporation was monitored at 2-
to 4-h intervals by liquid scintillation counting (11).
RNA isolation and analysis. Total cellular RNA was ex-
tracted with guanidine isothiocyanate and purified by cen-
trifugation through 5.7 M CsCl as previously described (10).
Samples (15 ,ug) were subjected to 1% agarose formaldehyde
gel electrophoresis and blotted onto nitrocellulose. Filters
were vacuum baked at 80°C for 90 min. Prehybridizations
were carried out for 8 to 24 h at 42°C in a solution containing
50% formamide, Sx SSC (1x SSC is 0.15 M NaCl plus 0.015
M sodium citrate [pH 7.0]), 5 x Denhardt's solution, 0.2%
sodium dodecyl sulfate (SDS), and 100 ,ug of heat-denatured
sheared salmon sperm DNA per ml. Hybridizations were
carried out for 48 to 72 h in identical conditions except for
the addition of 1.5 x 106 cpm of heat-denatured 32P-labeled
probes (specific activity, >1 x 109 cpm/l,g of DNA) per ml
of hybridization solution (19). Filters were washed for 10 min
at room temperature with 1 x SSC and 0.1% SDS, for 30 min
at 420C with 0.lx SSC and 0.1% SDS, and for 30 min at 55
to 65°C with 0.2x SSC and 0.1% SDS. Specific hybridization
signals were visualized by autoradiographic exposure to
Kodak XAR-5 film with Dupont Cronex intensifying
screens. The autoradiographic bands were quantitated by
scanning with an EC densitometer (EC Apparatus Corp., St.
Petersburg, Fla.). Radiolabeled probes were removed from
nitrocellulose filters by treatment with 0.1x SSC and 0.1%
SDS at 100°C for 20 min before subsequent hybridizations.
Probes. Plasmids containing cDNA inserts, which were
used as probes in Northern (RNA) blot analysis, were
generously provided by the following individuals: human
c-raf-1, U. Rapp (8); human p75 subunit of IL-2-R, W.
Leonard (24); human p55 subunit of IL-2-R, T. Honjo (44);
human IL-2, G. Crabtree (26); and rat 0-actin, B. M.
Paterson (32).
Western immunoblot analysis. PBMCs or primary or ex-
panded T cells (10 x 106 to 50 x 106) were spun down at 650
x g for 5 min, washed once with cold normal saline
containing 0.5 mM EDTA (pH 8.0) and 100 ,uM orthovana-
date, respun, and lysed as previously described (42) in 0.4 ml
of 1% Triton X-100 lysis buffer containing 20 mM Tris (pH
8.0), 137 mM NaCl, 10% glycerol, 2 mM EDTA (pH 8.0), 2
mM phenylmethylsulfonyl fluoride, aprotinin (0.15 trypsin-
inhibiting U/ml), 20 p.M leupeptin, 1 mM sodium vanadate, S
mM sodium fluoride, and 1 mM dithiothreitol at 4°C for 10
min. Insoluble material was removed by centrifugation at
4°C for 15 min at 10,000 x g. Cell lysates were normalized
for protein content by an adaptation of the bicinchoninic acid
protein assay (Pierce Chemical Company, Rockford, Ill.) as
previously described (50) before electrophoretic separation
by SDS-7.5% polyacrylamide gel electrophoresis (PAGE)
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and transferred to nitrocellulose filters as previously de-
scribed (42). Protein blots were probed with an anti-Raf-1
antibody, SP63, directed against the carboxy 12 residues of
Raf-1 (56), and immunological reactions were identified by
using an alkaline phosphatase detection system (Promega).
Protein band intensities were quantified by scanning the
blots into a Macintosh IIfx computer with a ScanJet Plus
flatbed scanner (Hewlett-Packard). Densitometry was per-
formed on the scanned image by using Scan Analysis (Bio-
soft, Cambridge, United Kingdom) and a customized version
of Enhance (Microfrontiers, Des Moines, Iowa). Serial dilu-
tions of cell lysates prepared from c-rafA cells, a Raf-1-
overproducing murine fibroblast cell line (42), were blotted
and scanned in order to determine that Raf-1 peak tracings
fell within a linear range of detection.
In vitro immune complex kinase assays. PBMCs or ex-
panded T cells (25 x 106 to 50 x 106) were lysed in Triton
lysis buffer in the presence of protease and phosphatase
inhibitors as described for Western blot analysis. Polyclonal
anti-Raf-1 serum was prepared and affinity purified as previ-
ously described (56). Affinity-purified antibody was coupled
to protein A-Sepharose beads by being incubated in 1.0 ml of
lysis buffer for 60 min at 4°C. Lysate, prepared from equiv-
alent cell numbers, was then added to the bead-antibody
complex and incubated for 3 to 6 h at 4°C. Immunoprecipi-
tates were washed once in lysis buffer, twice in 0.5 M
LiCl-0.1 M Tris (pH 7.4), and once in kinase buffer (25 mM
HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid; pH 7.4], 10 mM MgCl2). Kinase assays were performed
by adding 40 ,ul of kinase buffer (made 1 mM for dithiothre-
itol and 15 p.M for ATP) and 10 ,uCi of [-y-32P]ATP per
reaction for 20 min at 25°C. Reactions were terminated by
diluting into 1.0 ml of phosphate-buffered saline, washing
away the unincorporated [y-32P]ATP, and boiling the sam-
ples in electrophoresis buffer prior to SDS-PAGE.
RESULTS
Raf-1 expression is potentiated during T-cell cycle progres-
sion. In previous studies we established that after activation
of the TCR, T-cell cycle progression occurs asynchronously
because individual cells within the population express IL-
2-Rs asynchronously (12). Thus, even though the initiation
of cell cycle progression results from the instantaneous
activation via the TCR, the cells respond to the signal
heterogeneously. As shown in Fig. 1A, IL-2 mRNA tran-
scripts are expressed transiently, peak by 6 h, and then
decline to undetectable levels by 36 to 48 h. The levels of
IL-2-R p55 chain also become evident by 6 h after a-CD3
stimulation but do not peak until 24 to 36 h. The IL-2-R p75
mRNA transcripts also peak at 24 to 36 h after activation
(10).
Determination of c-raf-1 mRNA expression after a-CD3
stimulation revealed a time course remarkably similar to the
expression of the IL-2-R. Steady-state c-raf-1 transcripts
were detectable before stimulation and increased gradually
after stimulation, reaching peak levels of 8- to 10-fold 12 to
36 h after activation (Fig. 1A and B).
The increased c-raf-1 mRNA expression was paralleled by
augmented Raf-1 protein levels detected by Western blot
analysis, as shown in Fig. 1B. Maximal levels occurred
between 48 and 72 h after activation, increasing 8- to 12-fold
over the level present in unstimulated cells. Although max-
imum levels of c-raf-1 mRNA and Raf-1 protein occurred at
least 24 h after CD3 stimulation, a small increase in levels
was evident as early as at 3 h of activation, suggesting a
biphasic mode of induction. c-raf-1 mRNA and Raf-1 protein
levels in control, unactivated PBMCs remained at basal (t =
0) levels even after 120 h in culture (data not shown).
Also shown in Fig. 1D is a shift in the electrophoretic
mobility of Raf-1 molecules, such that at least two more
slowly migrating forms (from 72 to 76 kDa) were detectable
between 6 and 72 h after a-CD3 activation. Previous studies
have established that this mobility shift is indicative of an
increase in Raf-1 phosphorylation and is usually associated
with enhanced serine and threonine kinase activity in Raf-1
immunoprecipitates (2, 6, 30, 41, 42, 57).
The kinetics of Raf-1 induction after activation via a-CD3
were of interest in relationship to the transition from G1 to S
phase of the cell cycle, monitored by tritiated thymidine
([3H]TdR) incorporation. As shown in Fig. 1E, increased
Raf-1 protein expression preceded the onset of DNA repli-
cation by at least 12 h. Thereafter, Raf-1 levels remained
elevated and were in a highly phosphorylated state as long as
the cells continued to proliferate. When the cell population
was washed free of a-CD3 and any IL-2 produced in situ
after 72 h of culture, cell cycle progression gradually de-
clined; by 120 h, [3H]-TdR incorporation had decreased to t
= 0 levels. In parallel, c-raf-1 mRNA and protein levels fell
gradually; by 120 h they had decreased considerably com-
pared with peak levels between 48 and 72 h. Subsequently,
in noncycling cells there was also a dramatic decrease in the
extent of Raf-1 phosphorylation; by 120 h only one lower
migrating form of Raf-1 was evident (Fig. 1D).
Induction of c-raf-1 message expression by the TCR versus
that of the IL-2-R. Because IL-2 and IL-2-R expression
occur within 6 h ofTCR/CD3 activation, it was impossible to
ascertain which receptor system was responsible for the
effect on c-raf-1 and Raf-1 levels, which peaked much later.
Therefore, we capitalized on the observation that CsA
selectively prevents IL-2 production without impairing IL-
2-R expression after a-CD3 triggering (18, 53). As shown in
Table 1, CsA inhibited T-cell cycle progression by -94% as
monitored by [3H]TdR incorporation, yet it had no effect on
the four- to fivefold increase in c-raf-1 mRNA measured 6 h
after cx-CD3 triggering. Moreover, the increase in c-raf-1
transcripts at 6 h was not affected by treatment with CHX,
thereby indicating an immediate/early induction of c-raf-1
mRNA expression via the TCR/CD3 complex. By compari-
son, CsA suppressed the later augmentation of c-raf-1
mRNA determined at 48 h; control cells underwent a 15-fold
increase in c-raf-1 mRNA, but cells treated with CsA ex-
pressed about the same levels ofmRNA at 48 h that they had
after only 6 h. This later accumulation of c-raf-1 mRNA was
in response to IL-2 treatment, since IL-2 supplementation
largely overcame the suppressive effect of CsA.
IL-2-induced c-raf-1 mRNA expression. The results from
the CsA experiments indicated that both the TCR and the
IL-2-R stimulated the expression of c-raf-1 mRNA. To
further investigate the relative effects of the IL-2-R from
TCR triggering, we utilized our previous observations by
using expanded Gl-synchronized T-cell cultures (11, 62). T
cells were expanded selectively in IL-2 for 12 to 14 days and
then cultured for 48 h without IL-2 to allow their reaccumu-
lation into a quiescent, early G1 state. Subsequently, a brief
exposure to PdBU resulted in the rapid reexpression of
high-affinity IL-2-Rs (from <100 to -1,500 to 2,000 sites per
cell) without stimulating TCR triggering or IL-2 production
(11, 62). No increment in c-raf-1 mRNA expression occurred
after PdBU stimulation monitored after 1, 6, and 11 h of
PdBU treatment (data not shown). As depicted in Fig. 2, the
addition of human recombinant IL-2 promoted G1 progres-
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FIG. 1. c-raf-1 message and Raf-1 protein are increased following a-CD3 activation. (A) Autoradiographs of Northern blots showing the
time course of c-raf-1, IL-2, and IL-2-R (p55 and p75) expression in 15 ,ug of total cellular RNA isolated from PBMCs before or at various
times subsequent to a-CD3 activation. (B) Relative intensity of c-raf-1 signal with respect to resting (t = 0) PBMCs was measured by
densitometry. Error bars represent the standard deviation of values determined from scans of autoradiographs obtained from at least three
Northern blots of RNA isolated from three independent cell harvests. (C) The 28S and 18S ribosomal bands were visualized by ethidium
bromide staining used to affirm the integrity and equivalent loading of RNA in gels. (D) Immunoblot analysis showing Raf-1 protein expression
and changes in Raf-1 phosphorylation in a-CD3-activated PBMCs. Cell equivalents 2.5 x 106 were analyzed by SDS-PAGE. Protein blots
were probed with an anti-Raf-1 antibody and visualized by an alkaline phosphatase detection system. Molecular size markers are shown to
the left (in kilodaltons). (E) Raf-1 protein induction coincides with cell entry into DNA synthesis. Quantitation of Raf-1 protein expression
in the Western blot shown in panel D was determined by scanning and densitometry as described in Materials and Methods. Results are
representative of several experiments. A value of lOO1o corresponds to the maximal Raf-1 expression after 48 h of oa-CD3 stimulation. [3H]TdR
incorporation was monitored at 2-h intervals by liquid scintillation counting at various times following a-CD3 treatment. Results are expressed
as percent maximum incorporation, where 100% corresponds to a value of 1,225 cpmIh/104 cells. Standard error bars are not indicated for
reasons of clarity but were always <5% of the mean.
sion in a synchronous fashion, with S-phase transition first
becoming detectable via [3H]TdR incorporation after 10 to
12 h. The IL-2-R interaction resulted in a rapid induction of
c-raf-1 transcripts, which was first evident within 1 to 2 h and
continued to increase through Gl, reaching 8- to 10-fold-
greater levels within 10 to 12 h, just prior to the onset of
DNA synthesis (Fig. 2). Although not shown, CHX treat-
ment of T cells did not inhibit the IL-2-induced c-raf 1
message accumulation.
Effects of the TCR and IL-2-R on Raf-1 protein phosphor-
ylation and associated kinase activation. Given the -5-fold
increase in c-raf-1 message expression in response to stim-
ulation of the TCR and the further increase to -15-fold
following stimulation of the IL-2-R, we sought to determine
whether stimulation of either of these receptors led to a
modification of the c-raf-1 gene product.
Previous experiments have revealed that phosphorylation
of Raf-1 alters its electrophoretic mobility on SDS-PAGE
analysis (2, 6, 30, 41, 42). Phosphorylation occurs predomi-
nantly on serine and threonine residues and to a much lesser
extent on tyrosine (12a, 29, 42, 64a). Since the TCR is known
to activate tyrosine kinase activity in addition to serine- and
threonine-specific phosphorylation via activation of PKC
(43, 67), it was of interest to determine the effects of TCR
triggering on Raf-1 gel mobility. A representative experiment
in which Western blot analysis was used to detect Raf-1 is
shown in Fig. 3A. Before stimulation, freshly isolated resting
T cells contain Raf-1 protein that migrates as a single 72-kDa
band. No change in the electrophoretic mobility of the Raf-1
protein was observed after at-CD3 stimulation for 30 min,
whereas treatment with PMA at 50 ng/ml resulted in a
dramatic shift of the entire Raf-1 population of molecules to
A
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TABLE 1. c-raf-1 message induced via TCR and IL-2-R
Culture % [3H]TdR c-raf-1 mRNA levels' at:
additivea incorporationb 6 h 48 h
None 100.0 4.5 ± 1.95 15.8 ± 4.27
CsA 6.0 ± 3.45 4.2 ± 2.38 4.8 ± 1.42
CsA + IL-2 78.6 ± 13.00 6.3 ± 2.38 13.8 ± 3.08
CHX NDd 6.2 ± 0.64 ND
a Primary human T cells were isolated, and total cellular RNA was
extracted from control unactivated T cells (t = 0) and from ca-CD3-activated
T cells cultured in the presence or absence of CsA (1 ,ug/ml), exogenously
added IL-2 (500 pM), or CHX (10 FLg/ml) for various amounts of time before
being subjected to Northem blot analysis. In long-term cultures, media
containing CsA and IL-2 were replenished every 12 h. The T cells under all
experimental conditions were greater than 90%o viable as assayed by trypan
blue exclusion.
b Incorporation of [3HJTdR was monitored for a 2.5-h interval after 48 h in
culture and is represented as a percentage of maximum; 100o incorporation
(CD3 treatment) corresponds to a value of 926.2 + 18.94 cpm/h/104 cells and
represents the mean of three separate experiments in which n = 6.
c c-raf-1 message expression is shown relative to that of control, unacti-
vated (t = 0) cells. Results represent densitometric scan values (n = 3)
obtained from three Northern blots of three independent cell harvests.
d ND, Not done.
high-molecular-weight species. In addition to the Raf-1 pro-
tein migrating at 72 kDa, another protein may be seen just
below 68 kDa. This protein, the identity of which is un-
known, appears in most, but not all, immunoblots and never
appears in immunoprecipitates.
To compare the effects of TCR and IL-2-R triggering in
the same cell population, IL-2-Rs were first expressed on
PBMCs by a 3-day stimulation with ct-CD3. The cells were
then washed free of a-CD3 and allowed to become quiescent
for an additional 48 h (62). As shown in Fig. 3B, ot-CD3








electrophoretic mobility. By comparison, IL-2 exposure
induced a shift upward in the Raf-1 mobility that was evident
within 5 min and increased throughout a 60-min incubation.
A more extensive time course of the IL-2 effect on Raf-1
mobility is shown in Fig. 3C. It is evident that with pro-
longed exposure, i.e., 6, 10, and 14 h, a greater proportion of
Raf-1 molecules migrate at high molecular weights. PMA
induced an even greater shift in mobility than did IL-2,
whereas db-cAMP treatment (5 to 60 min) had no effect on
Raf-1 mobility. Expanded T-cell cultures differ from freshly
isolated T cells (Fig. 1D) in that Raf-1 protein is more
abundant in resting, expanded T cells (Fig. 3C). The 6-
through 14-h times represented in the Western blot shown in
Fig. 3C make it clear that in untreated cultured cells the level
of Raf-1 protein decreased dramatically relative to that in t =
0 cells. IL-2 treatment, which enhances the expression of
c-raf-1 message (Fig. 2), correlates with the maintenance of
high levels of Raf-1 protein in expanded T cells (Fig. 3C).
To determine whether the IL-2-induced shift in electro-
phoretic mobility of Raf-1 protein correlated with an activa-
tion of Raf-1-associated kinase activity, Raf-1 protein was
immunoprecipitated from control, IL-2-treated T cells and
from proliferating cells, for which an in vitro Raf-1-associ-
ated autokinase assay was performed. As shown in Fig. 4A,
the autoradiographic intensity of the 74-kDa Raf-1-associ-
ated protein was -25- to 30-fold greater on a per cell basis in
proliferating cells (48 h, a-CD3 activated) than in immuno-
precipitates prepared from freshly isolated cells or from cells
cultured without activation (t = 48 h, control). In order to
normalize for Raf-1 protein expression, a Western blot was
quantitated by using a parallel aliquot of T-cell lysates; the
Raf-1 protein was four- to fivefold greater at 48 h of activa-
tion relative to control cells (t = 0) (data not shown).
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FIG. 2. Kinetics of c-raf-1 mRNA accumulation during IL-2-induced T-cell cycle progression. IL-2-R-positive quiescent T cells (t = 0)
were stimulated into G1 cell cycle progression by the addition of IL-2 (1 nM) or kept in IL-2-free media as described in Materials and Methods.
Total cellular RNA was isolated at various times, and c-raf-1 message expression was evaluated by Northern blot analysis. The relative
intensity of the c-raf-1 signal with respect to resting (t = 0) cells without IL-2 (A) or with IL-2 (A) was measured by densitometry. Standard
error bars represent the compiled results from three to four independent Northern blots and cell harvests. The incorporation of [3H]TdR
without IL-2 (0) and with IL-2 (A) was monitored at 2- to 4-h intervals as indicated. Results are expressed as percent maximum incorporation,
where 100% equals a value of 331.3 + 88.56 cpm/h/104 cells, and are means of four representative experiments in which n = 6. In control cell
cultures lacking IL-2, [3H]TdR incorporation was <15 cpm/h/104 cells.
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FIG. 3. Effects of a-CD3, IL-2, db-cAMP, and PMA treatment on Raf-1 electrophoretic mobility. Raf-1 protein was detected by
immunoblot analysis and visualized by an alkaline phosphatase detection system. (A) Freshly isolated primary human T cells were harvested
(lane C) or activated with immobilized a-CD3 antibodies for various times. Parallel a-CD3-activated T-cell cultures were supplemented with
PMA (50 ng/ml) for 15 to 30 min prior to cell lysis. Molecular size standards (in kilodaltons) are indicated on the left. (B) Quiescent early G1
human T cells, which express both T-cell antigen and IL-2-Rs, were isolated (Materials and Methods). The resting T cells (lane C) were
harvested or treated with soluble CD3 (1:10,000 dilution), IL-2 (500 pM), PMA (50 ng/ml), or db-cAMP (0.5 mM) (60-min treatment shown)
for 5 to 60 min prior to Raf-1 immunoblot analysis. (C) Early Gl-synchronized IL-2-R-positive expanded human T cells were isolated as
described in Materials and Methods. The cells were kept in IL-2-free media or stimulated into G1 cell cycle progression by the addition of
saturating concentrations of IL-2 (1 nM) and were incubated at 37°C. Parallel early G1 cell cultures were treated with PMA (50 ng/ml) for 15
min. Cell lysates were prepared, normalized to per cell equivalents, and subjected to Raf-1 immunoblot analysis. These data are
representative of at least four independent cell harvests and Western blots.
kinase activity of five- to sixfold. The Raf-1 molecule dis-
played decreases in its electrophoretic migration upon acti-
vation, as previously illustrated in Fig. 1D.
As shown in Fig. 4B, the autoradiographic intensity of the
74-kDa Raf-l-associated protein after 5 min of IL-2 treat-
ment was enhanced approximately threefold relative to that
of control T cells (t = 0). The band intensity increased with
prolonged IL-2 exposure, reaching maximum levels of four-
to sixfold relative to those of controls between 6 and 10.5 h.
By comparison, PMA treatment caused a dramatic increase
in the electrophoretic shift of the related 74-kDa band and
revealed a concomitant -10-fold increase in its autoradio-
graphic intensity. Even so, as illustrated in Fig. 3A, TCR/
CD3 stimulation of primary T cells did not affect the elec-
trophoretic mobility of the Raf-1 protein. In addition, we
have not been able to detect an induction of Raf-1-associated
autokinase activity from Raf-1 immunoprecipitates after
TCR/CD3 triggering of primary T cells (data not shown).
A prominent protein of 112 kDa was also observed in
Raf-1 immunoprecipitates isolated from T cells whose auto-
radiographic intensity was moderately (1.4- to 3.0-fold)
affected by a-CD3 activation and IL-2 treatment (Fig. 4).
Characterization of this protein is in progress.
DISCUSSION
Although the cellular proto-oncogene c-raf-1 has been
implicated as functioning during cell cycle progression, its
precise role in this process has remained obscure. Most of
the work to date has dealt with early cellular activation
events associated with the G0/G1 transition in established
cell lines. By comparison, the findings with freshly isolated T
cells described in this report are noteworthy, since they
reveal that c-raf-1 message, Raf-1 protein expression, and
Raf-1-associated kinase activity are all stimulated markedly
through G1, reaching maximal levels just prior to the peak in
DNA replication.
In contrast to the findings reported here, c-raf-1 mRNA
levels are reported not to vary appreciably in a wide variety
of established mammalian cell lines, particularly at different
phases of the cell cycle. For example, mitogen treatment of
NIH 3T3 cells, IL-3-dependent cell lines, and IL-2-depen-
C
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FIG. 4. Raf-1-associated autokinase activity is elevated in proliferating T cells and after IL-2 stimulation. (A) Raf-1 was immunoprecip-
itated from lysates of freshly isolated (t = 0) human PBMCs or from 48-h ot-CD3-stimulated and 48-h unstimulated cells (harvested in
duplicate, lanes A and B). Raf-1-immune complexes, prepared from equivalent cell numbers (5 x 106), were washed, and Raf-1-associated
kinase activity was assayed by incubation with [-y-32P]ATP. Samples were analyzed on SDS-7.5% PAGE, and phosphoproteins were detected
by autoradiography. (B) Expanded human T cells were synchronized into early G1 by IL-2 deprivation and were then treated with IL-2 (1 nM)
or kept in IL-2-free media for 0 to 14 h. Parallel cultures were treated with PMA for 15 min. Cell lysates were prepared and Raf-1-associated
autokinase activity was assayed (from 5 x 10' cell equivalents) as described above for panel A.
dent cell lines does not affect Raf-1 mRNA expression (63).
We too have found that IL-2 stimulation of G1-synchronized
murine IL-2-dependent CTLL-2 cells does not influence the
level of c-raf-i mRNA transcripts (69). By comparison, the
expression of mRNA transcripts for several other proto-
oncogenes (e.g., c-fos, c-myc, and pim-J) is markedly en-
hanced by IL-2 in CTLL-2 cells (15). It should be empha-
sized that many established cell lines cannot be induced to
enter a true Go resting stage; they can only be retarded from
progressing from one phase of the active cell cycle to the
next (45). In contrast, human peripheral T cells exist phys-
iologically in a true metabolic and biochemical Go state.
Only upon activation of the TCRICD3 complex do they leave
Go and enter early G1 (14). Therefore, it is notable that Raf-1
protein is barely detectable in freshly isolated T cells and
only becomes readily manifest after triggering of the TCR/
CD3 complex.
Consistent with the proposed ubiquitous expression of
c-raf-i message, the 5' regulatory promoter region of the
c-raf-1 gene is GC rich, lacks TATA and CAAT boxes, and
contains four potential binding sites (GC boxes) for the
transcription factor SP1, all of which are characteristic
features of housekeeping genes (4). However, the basal
levels of c-raf-1 mRNA vary among cell types and are
elevated under deregulated proliferative states, which sug-
gests that tissue-specific factors, as well as growth factors,
may influence the positive or negative expression of c-raf-1
(33, 63). The c-raf-1 promoter also contains an octamer
enhancer element, ATGCAAAT (4), which may bind the
octamer series (Oct-i) transcription factors (47, 48). Human
pim-J and c-myb, two genes which are known to be tran-
scriptionally activated by IL-2, share identical housekeeping
motifs and, as well, contain the SPi- and Oct-l-binding
motifs in their regulatory promoter regions (5, 34). There-
fore, the interactions of specific DNA-binding proteins to
these sequences may compose a common mechanism by
which IL-2 regulates gene expression.
Many proteins whose expression has been shown to
increase are important molecules for signal transduction and
play a regulatory role in T-cell activation (14). Even though
the TCR/CD3 complex and the IL-2-R activate distinct
biochemical pathways, which result in altogether different
cellular changes, both of these cellular receptor systems
induce the rapid expression of c-raf-i mRNA, even when
protein synthesis is prevented. In this regard, several genes,
including c-fos, c-myc, and the IL-2-R p55 chain, are in-
duced by both receptor systems, whereas other genes are





IL-2 INDUCES Raf-1 AND KINASE ACTIVITY IN G1 AND S
other (46, 52). The timing of c-raf-1 expression (which is
significantly delayed relative to that of c-myc and c-fos, for
example) is more consistent with a regulated change in
expression than with a general increase in cellular metabo-
lism (14).
The TCR/CD3 complex triggers phosphatidyl-inositol
turnover with a resultant activation of PKC and a sustained
increase in the intracellular free calcium concentration (i.e.,
from 100 nM to 0.5 to 1.0 ,uM) (67). However, phorbol esters
(PMA and PdBU) failed to mimic the TCR and IL-2-R effect
of stimulating c-raf-1 mRNA expression (data not shown).
Moreover, IL-2 does not stimulate a rise in intracellular free
calcium (36), yet it clearly causes immediate/early c-raf-1
mRNA expression. Therefore, calcium-dependent path-
ways, particularly calcium-dependent kinases, are probably
not involved in either TCR or IL-2-R stimulation of c-raf-1
mRNA expression. Recent experimental evidence indicates
that tyrosine-specific protein kinase activation is an early
biochemical change common to both receptor signaling
pathways (55). Therefore, a reasonable working hypothesis
includes receptor-stimulated tyrosine phosphorylation of
molecules composing an immediate signaling pathway, lead-
ing to expression of a common set of genes.
Siegel and coworkers recently reported that activation of
murine T-cell hybridomas results in Raf-1 phosphorylation
and enhancement of Raf-1-associated kinase activity via a
PKC-dependent pathway (57). In support of their findings
and those of others, we have found that phorbol esters,
which activate PKC, promote a rapid mobility shift of the
entire Raf-1 population as well as enhanced Raf-1-associated
autokinase activity (42). However, stimulation of primary
human T cells with the a-CD3 monoclonal antibody 64.1 (22)
did not affect the electrophoretic mobility or the associated
autokinase activity of Raf-1. It is difficult to reconcile these
conflicting results at this time, but since IL-2 stimulates
phosphorylation and kinase activity associated with Raf-1 by
a PKC-independent mechanism, it appears that both PKC-
dependent and -independent pathways may be operative.
The combined effect of TCR and IL-2-R stimulation of
c-raf-1 mRNA results in up to a 12-fold increase in Raf-1
protein expression that accumulates throughout Gl. These
findings are consistent with the attainment of a crucial Raf-1
concentration during the latter half of G1 that is important
either for late G1 progression or for G1/S-phase transition. In
addition, because the IL-2-R interaction results in an imme-
diate phosphorylation of Raf-1 molecules, as detected by a
shift in electrophoretic mobility, and a concurrent activation
of Raf-1-associated kinase activity, our results suggest that
Raf-1 activity may also increase markedly throughout G1.
Therefore, the IL-2-R interaction serves two functions: to
increase the concentration of Raf-1 protein and to activate
the Raf-1-associated kinase activity.
The four- to sixfold increase in Raf-1-associated kinase
activity that accumulates during G1 is reminiscent of the
IL-2-R interaction threshold, which is crucial for IL-2-
induced G1 progression to DNA replication. The commit-
ment on the part of the T cell to enter S phase and
subsequent mitosis is a quantal event that depends upon
-10,000 IL-2-R interactions requiring at least 5 to 6 h of
continuous IL-2 stimulation (12). Since fully activated pri-
mary human T cells express only -1,000 high-affinity IL-2-R
per cell, this time interval depends upon the rate of new
receptor synthesis, which we have calculated to be -35
receptors per cell per min (59). Although the earliest bio-
chemical events in IL-2-R signaling still remain obscure,
recent reports have suggested that tyrosine-specific kinase
activity may be involved. The p75 subunit of the IL-2-R (1)
and intracellular proteins of -130,000, 100,000, 80,000, and
69,000 Da are rapidly phosphorylated on tyrosine residues
after IL-2 binding (35, 54). Therefore, the Raf-1 kinase may
be phosphorylated and activated by this signaling pathway,
either directly or indirectly soon after IL-2-R binding, by
analogy to the phosphorylation and activation of Raf-1 by
the PDGF-p receptor (41, 42).
We have not assessed tyrosine phosphorylation of Raf-1 in
response to stimulation by IL-2 in primary human T cells.
However, tyrosine phosphorylation of Raf-1 in lymphoid
and myeloid cells has been examined by several groups.
Tyrosine phosphorylation of Raf-1 was not detected follow-
ing colony-stimulating factor 1 stimulation of a macrophage
line (2). More germane to our study, IL-2 stimulation of the
murine T-cell line, CTLL-2, was reported to induce phos-
phorylation of Raf-1, with 50% of the new phosphate occur-
ring on tyrosine (64a). Similarly, IL-3 and granulocyte mac-
rophage colony-stimulating factor have been reported to
induce a significant level of tyrosine phosphorylation in
murine myeloid cell lines (12a). In a human myeloid line,
however, less than 2% of the increase in phosphorylation in
response to IL-3 and granulocyte macrophage colony-stim-
ulating factor was on tyrosine (29). Taken together, these
results suggest that at least some of the increased phosphor-
ylation of Raf-1 in response to stimulation of the IL-2/IL-3
family of receptors (28) is attributable to phosphotyrosine.
From the results described, further experiments exploring
the role of Raf-1 in IL-2-promoted G1 progression, G1/S-
phase transition, as well as in DNA synthesis, are now
warranted. A search for Raf-1 substrates important for cell
cycle progression should be undertaken. Obvious candidates
include the retinoblastoma gene product, Rb (9, 16, 20), and
the cdc2 catalytic seine- and threonine-specific kinase, p34
(17, 21, 31), proteins which are known to be phosphorylated
during G1 and at the G1/S-phase boundary.
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